Shots:Novartis has reported interim P-III (PSMAddition) trial data assessing Pluvicto + SoC (ARPI + ADT) vs SoC in PSMA+ mHSPC adults, with pts switching to Pluvicto upon confirmation of radiographic progression & per physician's discretionTrial met its 1EP of improved rPFS, with favorable OS trend (2EP) observed; data to be shared in future…
